Dabur Research Foundation

Fresenius Kabi Oncology Limited

Dabur Pharma Limited

Other

Manu Jaggi

Rama Mukherjee

Anand C Burman

Anu T Singh

Sudhanand Prasad

Sunder Ramadoss

Archna Mathur

Praveen Rajendran

Manoj Kumar Singh

Mohammad Jamshed Ahmad Siddiqui

Kamal K Kapoor

Dhiraj Khattar

Shobhit Kumar Singh

Gautam R Desiraju

Mukesh Kumar

Anand Vardhan

Rajan Sharma

Mohammad Jamshed Ahmed Siddiqui

Sarjana Dutt

Achla Behl Khanna

Sanjoy Mullick

Deepak Prusthy

Pawan Kumar Gupta

Rajendran Praveen

Mukund Keshav Gurjar

Jhillu Singh Yadav

Srivari Chandrasekhar

Vivek Kumar

Arvind Kumar Sharma

Shiv Kumar Agarwal

Manju Ray

Radhika Dilip Wakharkar

Asish Kumar Banerjee

Mohammad Jamshed Siddiqui

Archana Mathur

Kalapatapu V V M Sairam

Sankar Kumar Dutta

Venkatachalam Sesha Giri

Ashwini Nangia

Ajit Chand Kunwar

Tushar Kanti Chakraborty

Sanjay Kumar Srivastava

Hemant Kumar Jajoo

Nidhi Rani

K V V M Sairam

Sanjay Sarkhel

Anuo T Singh

Hanumant Bapu Rao Borate

The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions

The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(&#x2550;CH)CHor CH(CH); Rtogether with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; Ror Rare hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or Rand Rare combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and Ris zero when Y is O, and Ris hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells. 

Betulinic acid derivatives

The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.

Drug comprising synthetic peptide analogs for the treatment of cancer

The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of derivatives of cyclopentenone for the inhibition and/or prevention of cancer of the colon, pancreas, larynx, ovary, duodenum, kidney, oral cavity, prostate, lung, endothelial cells and leukemias.

Cyclopentenone derivatives for cancer therapy

Anticancer peptides which incorporate furanoid sugar amino acids and compositions made using these peptides are described. Methods for synthesis of the peptides and for preparing the furanoid sugar amino acids are disclosed. The peptides and compositions made using the peptides have pharmacological applications of these peptides especially in the treatment and prevention of cancer and tumors.

Peptides comprising furanoid sugar amino acids for the treatment of cancer

The present invention encompasses novel peptides that are antagonists to bombesin and bombesin like peptides and are useful in the treatment of cancer. The invention particularly relates to the design and synthesis of the novel peptides incorporating &#x3b1;,&#x3b1;-amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Bombesin analogs for treatment of cancer

The invention relates to the use of novel anthracene based compounds for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of hydroanthracene based compounds for the inhibition and/or prevention of cancer of the colon, pancreas, prostate, lung, larynx, ovary, breast, glioblastoma, oral cavity, endothelial cells and leukemias. The agents of the invention form a distinct class, distinct from the anthracene, anthrone or anthraquinone derivatives.

Hydroanthracene based compounds as anticancer agents

A polypeptide of the formula (I),P-L-P-L-P-L-P.

Polypeptides of covalently linked synthetic bioactive peptide analog(s) for treatment of cancer

This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention particularly relates to the synthesis of lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of VIP to its receptors. The invention encompasses methods for generation of these peptides, composition containing these peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Peptides for treatment of cancer

The invention relates to the use of betulinic acid derivatives for the inhibition and or prevention of cancer growth. The invention also relates to novel betulinic acid derivatives useful for inhibition of tumor cancer cells and a process for the preparation of the derivatives. The invention also relates to anti-leukemic and anti-lymphoma activity of the betulinic acid derivatives, and the use of the derivatives for the treatment of prostate, lung, laryngeal, colon and ovarian cancer.

Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid

The present invention provides for pharmaceutical compositions comprising carvedilol for treatment of cancer. More particularly the invention relates to the use of carvedilol for treatment of cancers of the colon, ovary, breast, prostate, pancreas, lung, melanoma, glioblastoma, oral cancer and leukemias. Although not bound to any theory, the anticancer activity of carvedilol appears to be attributed to the inhibition of Epidermal Growth Factor and Platelet derived growth factor dependent proliferation of cancer cells. Further, carvedilol exerts anticancer effect by inhibition of the Protein kinase C (PKC) activity and that of the cyclooxygenase 2 enzyme. The invention also relates to the anticancer activity of the optically pure isomers S(&minus;) and R(&plus;) of carvedilol and the use of carvedilol and its isomers in pharmaceutical compositions for the treatment of cancer.

Anti-cancer activity of carvedilol and its isomers

The invention relates to the use of imino acid conjugates of methylglyoxal for the inhibition and/or treatment of cancer. The invention relates more specifically to the use imino acid conjugates of methylglyoxal for inhibition and/or treatment of cancer of the Colon, Prostate, Larynx, Kidney, Pancreas, Lung, Breast, Intestine, Oral cavity, Ovary, Glioblastoma, and Leukemia. The invention also relates to compositions and methods of inhibiting cancer using imino acid conjugates of methylglyoxal.

Anticancer activity of imino acid conjugates or methylglyoxal

The present invention encompasses novel synthetic peptide analogs that are antagonists to Substance P, substance P like peptides and related peptides and are useful for the treatment of cancer. The invention particularly relates to the design and synthesis of the novel substance P antagonist analogs incorporating &agr;,&agr;-dialkylated amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing these peptides and pharmacological applications of these peptides specifically in the treatment and prevention of cancer.

Substance P analogs for the treatment of cancer

Growing community of inventors

Ghaziabad, India

Manu Jaggi